{
    "nctId": "NCT00633464",
    "briefTitle": "Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer",
    "officialTitle": "Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative (ER, PR, Her2 Negative) Locally Advanced Non-resectable and/or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Triple Negative Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 79,
    "primaryOutcomeMeasure": "Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female subjects with triple negative (ER, PR, and HER2 negative) locally advanced non-resectable and/or metastatic breast cancer\n* Prior adjuvant or neoadjuvant anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Tumors that are fluorescence in situ hybridization test (FISH) positive or immunohistochemistry (IHC) 3+\n* Neuropathy \\> Grade 1\n* Prior systemic therapy for metastatic disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}